Distinguished in Polymyalgia Rheumatica

Dr. William F. Rigby

Rheumatology
Dartmouth-Hitchcock Clinic
1 Medical Ctr Dr, 
Lebanon, NH 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Distinguished in Polymyalgia Rheumatica
Dartmouth-Hitchcock Clinic
1 Medical Ctr Dr, 
Lebanon, NH 
OverviewInsuranceLocationsClinical Research

Overview

William Rigby is a Rheumatologist in Lebanon, New Hampshire. Dr. Rigby and is rated as a Distinguished provider by MediFind in the treatment of Polymyalgia Rheumatica. His top areas of expertise are Rheumatoid Arthritis (RA), Arthritis, Rhizomelic Pseudopolyarthritis, and Polymyalgia Rheumatica. Dr. Rigby is currently accepting new patients.

His clinical research consists of co-authoring 60 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Rheumatology
Licenses
Internal Medicine in NH
Hospital Affiliations
Mary Hitchcock Memorial Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Anthem
  •  Humana

Locations

DARTMOUTH-HITCHCOCK CLINIC
1 Medical Ctr Dr, Lebanon, NH 03756

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Recruiting
Publish Date: January 22, 2025
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2025
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
Enrollment Status: Terminated
Publish Date: February 07, 2024
Intervention Type: Drug, Biological
Study Drugs: Otilimab, csDMARD
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Drug: Olokizumab
Study Phase: Phase 3
A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors
A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors
Enrollment Status: Completed
Publish Date: July 17, 2023
Intervention Type: Drug, Biological
Study Drugs: GSK3196165, Sarilumab, csDMARDs
Study Phase: Phase 3
View 5 Less Clinical Trials

60 Total Publications

The thematic role of extracellular loop of VraG in activation of the membrane sensor GraS in a cystic fibrosis MRSA strain differs in nuance from the CA-MRSA strain JE2.
The thematic role of extracellular loop of VraG in activation of the membrane sensor GraS in a cystic fibrosis MRSA strain differs in nuance from the CA-MRSA strain JE2.
Journal: PloS one
Published: April 14, 2022
Similar Doctors
Distinguished in Polymyalgia Rheumatica
Dr. Todd F. Dombrowski
Rheumatology
Distinguished in Polymyalgia Rheumatica
Dr. Todd F. Dombrowski
Rheumatology

Dartmouth-Hitchcock Clinic

590 Court St, 
Keene, NH 
 (50.2 mi)
603-354-5400
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Todd Dombrowski is a Rheumatologist in Keene, New Hampshire. Dr. Dombrowski and is rated as a Distinguished provider by MediFind in the treatment of Polymyalgia Rheumatica. His top areas of expertise are Polymyalgia Rheumatica, Rhizomelic Pseudopolyarthritis, Rheumatoid Arthritis (RA), and Temporal Arteritis. Dr. Dombrowski is currently accepting new patients.

Distinguished in Polymyalgia Rheumatica
Dr. Stephanie D. Mathew
Rheumatology
Distinguished in Polymyalgia Rheumatica
Dr. Stephanie D. Mathew
Rheumatology

Dartmouth-Hitchcock Clinic

1 Medical Ctr Dr, 
Lebanon, NH 
 (0.1 mi)
603-650-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Stephanie Mathew is a Rheumatologist in Lebanon, New Hampshire. Dr. Mathew and is rated as an Advanced provider by MediFind in the treatment of Polymyalgia Rheumatica. Her top areas of expertise are Juvenile Temporal Arteritis, Giant Cell Arteritis (GCA), Temporal Arteritis, and Polymyalgia Rheumatica. Dr. Mathew is currently accepting new patients.

Advanced in Polymyalgia Rheumatica
Dr. Kevin D. Kerin
Rheumatology
Advanced in Polymyalgia Rheumatica
Dr. Kevin D. Kerin
Rheumatology

Dartmouth-Hitchcock Clinic

1 Medical Ctr Dr, 
Lebanon, NH 
 (0.1 mi)
603-650-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kevin Kerin is a Rheumatologist in Lebanon, New Hampshire. Dr. Kerin and is rated as a Distinguished provider by MediFind in the treatment of Polymyalgia Rheumatica. His top areas of expertise are Raynaud Phenomenon, Rheumatoid Arthritis (RA), Juvenile Temporal Arteritis, and Giant Cell Arteritis (GCA). Dr. Kerin is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile